Reassurance on infection risk with checkpoint inhibitors

Rates of infection appear similar in patients with solid tumours before and after they receive immune checkpoint inhibitor (ICI) therapy. A retrospective study from the Canberra Hospital assessed infection rates in 327 patients who commenced ICIs between 2012 and 2019....

Rates of infection appear similar in patients with solid tumours before and after they receive immune checkpoint inhibitor (ICI) therapy. A...

Public Health

Are chronic disease hospitalisations preventable? A new study suggests not

Almost half of hospitalisations for chronic conditions that are classified as “potentially preventable” could not have been prevented by different care or patient behaviour in the previous three months, according to an Australia-first study. The authors say their findings raise questions...

Almost half of hospitalisations for chronic conditions that are classified as “potentially preventable” could not have been prevented by different...

Lung

Lung cancer screening adherence doesn’t match trial rates

In a major reality check for lung cancer screening advocates, adherence rates in the real world are a far cry from the achievements seen in RCTs such as the NELSON and NLST trials. A systematic review and meta-analysis of the...

In a major reality check for lung cancer screening advocates, adherence rates in the real world are a far cry...

Breast

Fulvestrant won’t be PBS listed for women with HR+ breast cancer

A PBS listing appears unlikely for fulvestrant for women with hormone receptor positive metastatic breast cancer because of disagreement over pricing, a patient advocacy group says. The selective oestrogen receptor down‐regulator (SERD) has received a positive recommendation from the Pharmaceutical Benefits...

A PBS listing appears unlikely for fulvestrant for women with hormone receptor positive metastatic breast cancer because of disagreement over...